- Home
- CANF vs FRSX Comparison
CANF vs FRSX Comparison
Compare CANF & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | FRSX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.8M |
| IPO Year | 2011 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CANF | FRSX |
|---|---|---|
| Price | $3.45 | $1.96 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 938.6K | 39.6K |
| Earning Date | 03-26-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,715,455.50 | N/A |
| Revenue Next Year | $101.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.31 |
| 52 Week High | $10.40 | $3.00 |
Technical Indicators
Market Signals| Indicator | CANF | FRSX |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 40.59 |
| Support Level | $2.89 | $0.83 |
| Resistance Level | $4.74 | $2.33 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 52.80 | 15.56 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About FRSX Foresight Autonomous Holdings Ltd.
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.